Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Med Virol ; 95(2): e28470, 2023 02.
Article in English | MEDLINE | ID: covidwho-2173232

ABSTRACT

Due to the COVID-19 pandemic, a series of sequelae, such as fatigue, tachypnea, and ageusia, appeared in long COVID patients, but the pathological basis was still uncertain. The targeted radiopharmaceuticals were of potential to systemically and dynamically trace the pathological changes. For the key ACE2 protein in the virus-host interaction, 68 Ga-cyc-DX600 was developed on the basis of DX600 as a PET tracer of ACE2 fluctuation and maintained the ability in differentiating ACE and ACE2. In the temporary infection model inhaled with the radio-traceable pseudovirus in the upper respiratory tract of male humanized ACE2 (hACE2) mice, organ-specific ACE2 dysfunction in acute period and the following ACE2 recovery in a relatively long period was visualized and quantified by ACE2 PET, revealing a complex pattern of virus concentration-dependent degree and time period-dependent tendency of ACE2 recovery, mainly a sudden decrease of apparent ACE2 in the heart, liver, kidneys, lungs, and so on, but the liver was of a quick functional compensation on ACE2 expression after a temporary decrease. ACE2 expression of most organs has recovered to a normal level at 15 days post inhalation, with brain and genitals still of a decreased SUVACE2 ;  meanwhile, kidneys were of an increased SUVACE2 . These findings on ACE2 PET were further verified by western blot. When compared with high-resolution computed tomography on structural changes and FDG PET on glycometabolism, ACE2 PET was superior in an earlier diagnostic window during infection and more comprehensive understanding of functional dysfunction post-infection. In the respective ACE2 PET/CT and ACE2 PET/MR scans of a volunteer, the repeatability of SUVACE2 and the ACE2 specificity were further confirmed. In conclusion, 68 Ga-cyc-DX600 was developed as an ACE2-specific tracer, and the corresponding ACE2 PET revealed the dynamic patterns of functional ACE2 recovery and provided a reference and approach to explore the ACE2-related pathological basis of sequelae in long COVID.


Subject(s)
COVID-19 , Male , Humans , Mice , Animals , Peptidyl-Dipeptidase A/metabolism , SARS-CoV-2/metabolism , Angiotensin-Converting Enzyme 2 , Post-Acute COVID-19 Syndrome , Pandemics , Positron Emission Tomography Computed Tomography
2.
Economic Research-Ekonomska Istraživanja ; : 1-26, 2022.
Article in English | Web of Science | ID: covidwho-2134038

ABSTRACT

The existing studies rarely reveal the reasons for the digital currency price fluctuation from the perspective of internal interaction and contagion. Therefore, to fill this research gap, this paper comprehensively adopts the dynamic conditional correlation (DCC-) GARCH model and wavelet coherence analysis (WTC) to reveal the internal correlation and formation reasons of digital currency price fluctuations. Our research has the following findings: (1) the price fluctuations of digital currency are highly related. Through the observation of the dynamic conditional correlation coefficient graph, it is found that the price fluctuations have a strong time-varying trend, manifested as a 'contagious' characteristic. (2) During the outbreak of COVID-19, most digital currencies have shown positive resonance in the short, medium, and long term, suggesting that the COVID-19 pandemic has increased the correlation and contagion of digital currency price fluctuations. (3) In the short term, Bitcoin is the main 'contagious source' of digital currency price fluctuation. But in the medium and long term, Ethereum and Ripple, which are closely related to the real economy, have a greater impact and become the new 'contagious source'. Generally speaking, Bitcoin, Ethereum, and Ripple are the internal causes of instability in the digital currency market. Finally, based on the empirical conclusion, this paper proposes that the digital currency portfolio should be optimized to meet the investment demand;strengthen digital currency regulatory cooperation, and improve regulatory efficiency. Let the digital currency return to the 'currency' attribute and serve the real economy.

3.
J Integr Med ; 20(5): 416-426, 2022 09.
Article in English | MEDLINE | ID: covidwho-1907343

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused an extensive burden to the world. Consequently, a large number of clinical trials have examined the efficacy of traditional Chinese medicine (TCM) for treating and preventing COVID-19, with coinciding proliferation of reviews summarizing these studies. OBJECTIVE: This study aimed to evaluate the methodological quality and evidence quality of systematic reviews and meta-analyses on the efficacy of TCM. SEARCH STRATEGY: Seven electronic databases, including PubMed, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Chongqing VIP, Wanfang Data and SinoMed, were searched for systematic reviews and meta-analyses in October 2021. Search terms such as "Chinese medicine," "Lianhua Qingwen" and "COVID-19" were used. INCLUSION CRITERIA: Systematic reviews and meta-analyses of randomized controlled trials that evaluated the efficacy of TCM treatment of COVID-19 were included. DATA EXTRACTION AND ANALYSIS: A Measurement Tool to Assess Systematic Reviews Version 2.0 (AMSTAR 2) was used to evaluate the methodological quality. The quality of evidence was graded using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Data extraction and analysis were performed by two reviewers independently. RESULTS: There were 17 meta-analyses included in our overview. The intervention group was defined as TCM combined with Western medicine, while the control group was Western medicine alone. The methodological quality of all the included studies was moderate to poor. A total of 89 outcome indicators were evaluated, of which, 8 were rated as moderate quality, 39 as low quality, and 41 as very low quality. Only one outcome measure was graded as being of high quality. The moderate quality of evidence indicated that, for the treatment of COVID-19, the clinical efficacy of TCM in combination with Western medicine was better, in terms of lung recovery, rate of conversion to severe/critical cases, symptom scores, duration of symptoms, mortality, and length of hospital stay. CONCLUSION: Evidence from the included studies shows that, compared with conventional Western medical therapy alone, the addition of TCM to COVID-19 treatment may improve clinical outcomes. Overall, the quality of evidence of TCM for COVID-19 was moderate to poor. Meta-analyses of the use of TCM in the treatment of COVID-19 can be used for clinical decision making by accounting for the experiences of clinical experts, medical policies, and other factors.


Subject(s)
COVID-19 Drug Treatment , Drugs, Chinese Herbal , Drugs, Chinese Herbal/therapeutic use , Humans , Medicine, Chinese Traditional , Meta-Analysis as Topic , Systematic Reviews as Topic , Treatment Outcome
4.
J Hazard Mater ; 427: 128139, 2022 04 05.
Article in English | MEDLINE | ID: covidwho-1587273

ABSTRACT

Increased worldwide consumption of antiviral drugs (AVDs) amid COVID-19 has induced enormous burdens to the existing wastewater treatment systems. Microalgae-based bioremediation is a competitive alternative technology due to its simultaneous nutrient recovery and sustainable biomass production. However, knowledge about the fate, distribution, and interaction of AVDs with microalgae is yet to be determined. In this study, a concentration-determined influence of AVD oseltamivir (OT) was observed on the biochemical pathway of Chlorella sorkiniana (C.S-N1) in synthetic municipal wastewater. The results showed that high OT concentration inhibited biomass growth through increased oxidative stress and restrained photosynthesis. Nevertheless, complete OT removal was achieved at its optimized concentration of 10 mg/L by various biotic (82%) and abiotic processes (18.0%). The chemical alterations in three subtypes of extracellular polymeric substances (EPS) were primarily investigated by electrostatic (OT +8.22 mV vs. C.S-N1 -18.31 mV) and hydrophobic interactions between EPS-OT complexes supported by secondary structure protein analysis. Besides, six biodegradation-catalyzed transformation products were identified by quadrupole-time-of-flight mass spectrometer and by density functional theory. Moreover, all the TPs exhibited log Kow ≤ 5 and bioconcentration factor values of < 5000 L/kg, meeting the practical demands of environmental sustainability. This study broadens our understanding of microalgal bioadsorption and biodegradation, promoting microalgae bioremediation for nutrient recovery and AVDs removal.


Subject(s)
COVID-19 , Chlorella , Microalgae , Biomass , Humans , Oseltamivir , SARS-CoV-2 , Wastewater
5.
Open Forum Infect Dis ; 7(6): ofaa187, 2020 Jun.
Article in English | MEDLINE | ID: covidwho-1109308

ABSTRACT

BACKGROUND: The clinical manifestations and factors associated with the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections outside of Wuhan are not clearly understood. METHODS: All laboratory-confirmed cases with SARS-Cov-2 infection who were hospitalized and monitored in Guangzhou Eighth People's Hospital were recruited from January 20 to February 10. RESULTS: A total of 275 patients were included in this study. The median patient age was 49 years, and 63.6% had exposure to Wuhan. The median virus incubation period was 6 days. Fever (70.5%) and dry cough (56.0%) were the most common symptoms. A decreased albumin level was found in 51.3% of patients, lymphopenia in 33.5%, and pneumonia based on chest computed tomography in 86%. Approximately 16% of patients (n = 45) had severe disease, and there were no deaths. Compared with patients with nonsevere disease, those with severe disease were older, had a higher frequency of coexisting conditions and pneumonia, and had a shorter incubation period (all P < .05). There were no differences between patients who likely contacted the virus in Wuhan and those who had no exposure to Wuhan. Multivariate logistic regression analysis indicated that older age, male sex, and decreased albumin level were independently associated with disease severity. CONCLUSIONS: Most of the patients infected with SARS-CoV-2 in Guangzhou, China are not severe cases and patients with older age, male, and decreased albumin level were more likely to develop into severe ones.

6.
Academic Journal of Second Military Medical University ; 41(4):409-413, 2020.
Article in Chinese | GIM | ID: covidwho-823639

ABSTRACT

Due to the high infection and occult onset of Coronavirus disease 2019 (COVID-19), the procedure and management of nuclear medicine imaging examination during COVID-19 epidemic period should be arranged according to the infection risk of the patients to improve the prevention and control management. According to the clinical manifestations and epidemiological history of the patients, the infection risk was stratified, and the corresponding prevention and control suggestions were put forward according to the characteristics of nuclear medical imaging. It is crucial to distinguish patients in the incubation period and the susceptible virus carriers before the examination. The patients should be divided into regular group, potential risk group, high risk group and suspected group, and then examinations should be given to patients with infection risk from low to high, during which the medical workers should adopt corresponding personal protection, with the environment and equipment properly disinfected afterward. The corresponding arrangement and prevention and control management based on the infection risk of patients can help to avoid cross infection of patients, ensure the safety of medical workers and meet the clinical needs.

7.
Int J Infect Dis ; 98: 252-260, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-621963

ABSTRACT

OBJECTIVE: The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, but the factors influencing viral RNA shedding, which would help inform optimal control strategies, remain unclear. METHODS: The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were evaluated retrospectively. RESULTS: The median duration of viral RNA shedding was 12 days (interquartile range 8-16 days) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA clearance within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.98-1.00; p = 0.04), time lag from illness onset to hospital admission (HR 0.91, 95% CI 0.88-0.94; p < 0.001), diarrhea (HR 0.59, 95% CI 0.36-0.96; p = 0.036), corticosteroid treatment (HR 0.60, 95% CI 0.39-0.94; p = 0.024), and lopinavir/ritonavir use (HR 0.70, 95% CI 0.52-0.94; p = 0.014) were significantly and independently associated with prolonged viral RNA shedding. CONCLUSIONS: Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding.


Subject(s)
Betacoronavirus/genetics , Coronavirus Infections/virology , Pneumonia, Viral/virology , RNA, Viral/genetics , Virus Shedding , Adult , Aged , Betacoronavirus/isolation & purification , Betacoronavirus/physiology , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/drug therapy , Female , Hospitalization , Humans , Lopinavir/therapeutic use , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/drug therapy , RNA, Viral/metabolism , Retrospective Studies , Ritonavir/therapeutic use , SARS-CoV-2 , Virus Shedding/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL